These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 25271887)

  • 41. Timed function tests, motor function measure, and quantitative thigh muscle MRI in ambulant children with Duchenne muscular dystrophy: A cross-sectional analysis.
    Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Schroeder J; Naduvilekoot Devasia A; Zuesli S; Bernert G; Laugel V; Bloetzer C; Steinlin M; Capone A; Gloor M; Tobler P; Haas T; Bieri O; Zumbrunn T; Fischer D; Bonati U
    Neuromuscul Disord; 2018 Jan; 28(1):16-23. PubMed ID: 29174526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 3 randomized placebo-controlled trial of tadalafil for Duchenne muscular dystrophy.
    Victor RG; Sweeney HL; Finkel R; McDonald CM; Byrne B; Eagle M; Goemans N; Vandenborne K; Dubrovsky AL; Topaloglu H; Miceli MC; Furlong P; Landry J; Elashoff R; Cox D;
    Neurology; 2017 Oct; 89(17):1811-1820. PubMed ID: 28972192
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.
    Mendell JR; Goemans N; Lowes LP; Alfano LN; Berry K; Shao J; Kaye EM; Mercuri E;
    Ann Neurol; 2016 Feb; 79(2):257-71. PubMed ID: 26573217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy.
    Bello L; Piva L; Barp A; Taglia A; Picillo E; Vasco G; Pane M; Previtali SC; Torrente Y; Gazzerro E; Motta MC; Grieco GS; Napolitano S; Magri F; D'Amico A; Astrea G; Messina S; Sframeli M; Vita GL; Boffi P; Mongini T; Ferlini A; Gualandi F; Soraru' G; Ermani M; Vita G; Battini R; Bertini E; Comi GP; Berardinelli A; Minetti C; Bruno C; Mercuri E; Politano L; Angelini C; Hoffman EP; Pegoraro E
    Neurology; 2012 Jul; 79(2):159-62. PubMed ID: 22744661
    [TBL] [Abstract][Full Text] [Related]  

  • 45. North Star Ambulatory Assessment changes in ambulant Duchenne boys amenable to skip exons 44, 45, 51, and 53: A 3 year follow up.
    Coratti G; Pane M; Brogna C; Ricotti V; Messina S; D'Amico A; Bruno C; Vita G; Berardinelli A; Mazzone E; Magri F; Ricci F; Mongini T; Battini R; Bello L; Pegoraro E; Baranello G; Previtali SC; Politano L; Comi GP; Sansone VA; Donati A; Hogrel JY; Straub V; De Lucia S; Niks E; Servais L; De Groot I; Chesshyre M; Bertini E; Goemans N; Muntoni F; Mercuri E;
    PLoS One; 2021; 16(6):e0253882. PubMed ID: 34170974
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids.
    Duong T; Canbek J; Fernandez-Fernandez A; Henricson E; Birkmeier M; Siener C; Tesi Rocha C; McDonald C; Gordish-Dressman H;
    J Neuromuscul Dis; 2022; 9(1):147-159. PubMed ID: 34719507
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Upper limb function in Duchenne muscular dystrophy: 24 month longitudinal data.
    Pane M; Coratti G; Brogna C; Mazzone ES; Mayhew A; Fanelli L; Messina S; D'Amico A; Catteruccia M; Scutifero M; Frosini S; Lanzillotta V; Colia G; Cavallaro F; Rolle E; De Sanctis R; Forcina N; Petillo R; Barp A; Gardani A; Pini A; Monaco G; D'Angelo MG; Zanin R; Vita GL; Bruno C; Mongini T; Ricci F; Pegoraro E; Bello L; Berardinelli A; Battini R; Sansone V; Albamonte E; Baranello G; Bertini E; Politano L; Sormani MP; Mercuri E
    PLoS One; 2018; 13(6):e0199223. PubMed ID: 29924848
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD003725. PubMed ID: 18254031
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.
    Willcocks RJ; Rooney WD; Triplett WT; Forbes SC; Lott DJ; Senesac CR; Daniels MJ; Wang DJ; Harrington AT; Tennekoon GI; Russman BS; Finanger EL; Byrne BJ; Finkel RS; Walter GA; Sweeney HL; Vandenborne K
    Ann Neurol; 2016 Apr; 79(4):535-47. PubMed ID: 26891991
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.
    Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M
    BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Glucocorticoid corticosteroids for Duchenne muscular dystrophy.
    Manzur AY; Kuntzer T; Pike M; Swan A
    Cochrane Database Syst Rev; 2004; (2):CD003725. PubMed ID: 15106215
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys.
    Pane M; Mazzone ES; Sivo S; Fanelli L; De Sanctis R; D'Amico A; Messina S; Battini R; Bianco F; Scutifero M; Petillo R; Frosini S; Scalise R; Vita GL; Bruno C; Pedemonte M; Mongini T; Pegoraro E; Brustia F; Gardani A; Berardinelli A; Lanzillotta V; Viggiano E; Cavallaro F; Sframeli M; Bello L; Barp A; Busato F; Bonfiglio S; Rolle E; Colia G; Bonetti A; Palermo C; Graziano A; D'Angelo G; Pini A; Corlatti A; Gorni K; Baranello G; Antonaci L; Bertini E; Politano L; Mercuri E
    PLoS Curr; 2014 Oct; 6():. PubMed ID: 25642376
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Developing a Natural History Progression Model for Duchenne Muscular Dystrophy Using the Six-Minute Walk Test.
    Hamuro L; Chan P; Tirucherai G; AbuTarif M
    CPT Pharmacometrics Syst Pharmacol; 2017 Sep; 6(9):596-603. PubMed ID: 28643370
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew A; Cano S; Scott E; Eagle M; Bushby K; Muntoni F;
    Dev Med Child Neurol; 2011 Jun; 53(6):535-42. PubMed ID: 21410696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy.
    Nagy S; Schmidt S; Hafner P; Klein A; Rubino-Nacht D; Gocheva V; Bieri O; Vuillerot C; Bonati U; Fischer D
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30688316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 59. A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy.
    Goemans N; Mercuri E; Belousova E; Komaki H; Dubrovsky A; McDonald CM; Kraus JE; Lourbakos A; Lin Z; Campion G; Wang SX; Campbell C;
    Neuromuscul Disord; 2018 Jan; 28(1):4-15. PubMed ID: 29203355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Atkinson L; Elfring GL; Reha A; Miller LL
    Muscle Nerve; 2010 Dec; 42(6):966-74. PubMed ID: 21038378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.